1. Home
  2. PGP vs BDSX Comparison

PGP vs BDSX Comparison

Compare PGP & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Global StocksPlus & Income Fund of Beneficial Interest

PGP

Pimco Global StocksPlus & Income Fund of Beneficial Interest

HOLD

Current Price

$8.64

Market Cap

102.9M

Sector

Finance

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$14.23

Market Cap

122.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGP
BDSX
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Precision Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.9M
122.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PGP
BDSX
Price
$8.64
$14.23
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
40.1K
71.5K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
10.84%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
N/A
$25.26
Revenue Next Year
N/A
$19.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$6.83
$0.25
52 Week High
$9.41
$20.21

Technical Indicators

Market Signals
Indicator
PGP
BDSX
Relative Strength Index (RSI) 52.36 48.15
Support Level $8.57 $6.33
Resistance Level $8.71 $20.21
Average True Range (ATR) 0.20 1.22
MACD 0.07 -0.24
Stochastic Oscillator 87.14 35.06

Price Performance

Historical Comparison
PGP
BDSX

About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest

PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: